6-(piperazin-1-yl)pyridine-3-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 6-(piperazin-1-yl)pyridine-3-carboxylic acid
• 英文别名: 6-piperazinylpyridine-3-carboxylic acid；6-(1-piperazinyl)nicotinic acid；6-Piperazin-4-ium-1-ylpyridine-3-carboxylate
• 化学式: C₁₀H₁₃N₃O₂
• 分子量: 207.232
• InChiKey: UMYHUVUKIGFYAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  65.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  6-氯烟酸甲酯 在 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 6-(piperazin-1-yl)pyridine-3-carboxylic acid
  参考文献：
  名称：

  [EN] BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF
  [FR] AGENTS DE DÉGRADATION BIFONCTIONNELS DE LA KINASE PROGÉNITRICE HÉMATOPOÏÉTIQUE ET LEURS UTILISATIONS THÉRAPEUTIQUES

  摘要：

  本公开提供了通过泛素蛋白酶体途径作为HPK1降解剂的双功能化合物，以及治疗受HPK1调节的疾病的方法。

  公开号：

  WO2021226262A1

文献信息

• GLYCINE COMPOUND
  申请人：Yoshihara Kousei

  公开号：US20120184520A1

  公开（公告）日：2012-07-19

  [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.

  本发明提供了一种化合物，该化合物可用作药物组合物的活性成分，特别是用于预防和/或治疗与VAP-1相关的疾病的药物组合物。 本发明的解决方案是，本发明者对具有VAP-1抑制活性的化合物进行了深入研究，结果发现本发明的化合物或其盐表现出优异的VAP-1抑制活性，并且对于预防和/或治疗与VAP-1相关的疾病，特别是糖尿病肾病或糖尿病黄斑水肿，具有用处，从而完成了本发明。本发明还涉及一种药物组合物，特别是用于预防和/或治疗与VAP-1相关的疾病的药物组合物，其包括本发明的化合物或其盐以及赋形剂。
• NOVEL INHIBITORS OF HEPATITIS C VIRUS
  申请人：McKINNELL Robert Murray

  公开号：US20120114600A1

  公开（公告）日：2012-05-10

  The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

  该发明提供了以下式(I)的化合物： 其中变量在规范中定义，或其药用可接受盐，这些化合物是乙型肝炎病毒复制的抑制剂。该发明还提供了包括这些化合物的药物组合物，使用这些化合物治疗乙型肝炎病毒感染的方法，以及用于制备这些化合物的工艺和中间体。
• Diacylglycerol Acyltransferase Inhibitors
  申请人：Bolin David Robert

  公开号：US20100113782A1

  公开（公告）日：2010-05-06

  Provided herein are compounds of the formula (I): were R1 is phenyl, R2 is hydrogen, halogen or lower alkyl, X is carbon on nitrogen, and R3 is isoquinoline, -amino, or a 4- to 6-membered heterocycloalkyl ring and pharmaceutically acceptable salts thereof, which are active as DGAT inhibitors and therefore find uses in treatment of diseases associated with abnormal metabolism of triglicerides such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

  本文提供了化合物的公式（I）：其中R1为苯基，R2为氢、卤素或低碳烷基，X为碳或氮，R3为异喹啉基、氨基或含有4至6个成员的杂环烷基环，并且其药学上可接受的盐，这些化合物作为DGAT抑制剂具有活性，因此可用于治疗与三酸甘油酯异常代谢相关的疾病，例如肥胖症、2型糖尿病和代谢综合征。
• Nicotinic acid derivatives and pharmaceutical compositions comprising
  申请人：Nisshin Flour Milling Co., Ltd.

  公开号：US05025012A1

  公开（公告）日：1991-06-18

  Compounds are disclosed of the formula ##STR1## wherein R.sub.1 is hydrogen or C.sub.1 -C.sub.6 alkyl; Y is --CH.sub.2 --, --O--, ##STR2## R.sub.2 is C.sub.1 -C.sub.6 alkyl; C.sub.2 -C.sub.6 alkenyl; C.sub.3 -C.sub.6 cycloalkyl; phenyl which may be mono- or di-substituted on the phenyl ring with C.sub.1 -C.sub.6 alkoxy; aralkyl which may be mono- or di-substituted on the aromatic ring with C.sub.1 -C.sub.6 alkoxy; diphenylmethyl; carboalkoxy; or an O- or N-heterocyclic radical which is linked to the nitrogen atom via carbonyl or carbonylmethylene; m is 2 or 3; and n is 0 or 1, and physiologically acceptable acid addition salts thereof. The compounds of formula (I) are of a blood flow-increasing action and can be used for the therapy or prevention of diseases in the cardiovascular system.

  该化合物的结构式如下：其中R.sub.1是氢或C.sub.1 -C.sub.6烷基；Y是--CH.sub.2 --，--O--，R.sub.2是C.sub.1 -C.sub.6烷基；C.sub.2 -C.sub.6烯基；C.sub.3 -C.sub.6环烷基；苯基，苯环上可能是单取代或双取代的C.sub.1 -C.sub.6烷氧基；芳基烷基，芳环上可能是单取代或双取代的C.sub.1 -C.sub.6烷氧基；二苯甲基；羧酸烷酯；或者通过羰基或羰基甲烯基与氮原子相连的O-或N-杂环基团；m为2或3；n为0或1，及其生理上可接受的酸盐。公式（I）中的化合物具有增加血流的作用，可用于治疗或预防心血管系统疾病。
• [EN] PYRROLIDINE N-BENZYL DERIVATIVES<br/>[FR] DÉRIVÉS N-BENZYLIQUES DE PYRROLIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010040663A1

  公开（公告）日：2010-04-15

  The present invention relates to a compound of formula (I) wherein Ar1 is aryl or heteroaryl; Ar2 is aryl or heteroaryl; R1 is hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, S-lower alkyl, -S(O)2-lower alkyl, -S(O)2-di- lower alkyl amino, cyano, amino, mono or di- lower alkyl amino, C(O)-lower alkyl, NHC(O)-lower alkyl, cycloalkyl, heterocyclyl, or is heteroaryl, optionally substituted by lower alkyl; R2 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen or cyano; R3 is hydrogen, halogen, lower alkyl or lower alkyl substituted by halogen; n is 1, 2 or 3; in case n is 2 or 3, R1 may be the same or different; o is 1, 2 or 3; in case o is 2 or 3, R2 may be the same or different; p is 1, 2 or 3; in case p is 2 or 3, R4 may be the same or different; or to a pharmaceutically active salt, to all stereoisomeric forms, including individual diastereoisomers and enantiomers as well as to racemic and non-racemic mixtures thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  本发明涉及一种具有以下结构的化合物（I）其中Ar1是芳基或杂环芳基；Ar2是芳基或杂环芳基；R1是氢、卤素、羟基、低碳基、低碳氧基、被卤素取代的低碳基、被卤素取代的低碳氧基、S-低碳基、-S（O）2-低碳基、-S（O）2-二低碳基氨基、氰基、氨基、单或双低碳基氨基、C（O）-低碳基、NHC（O）-低碳基、环烷基、杂环烷基，或者是杂环芳基，可以被低碳基取代；R2是氢、卤素、低碳基、低碳氧基、被卤素或氰基取代的低碳基；R3是氢、卤素、低碳基或被卤素取代的低碳基；n为1、2或3；如果n为2或3，R1可以相同也可以不同；o为1、2或3；如果o为2或3，R2可以相同也可以不同；p为1、2或3；如果p为2或3，R4可以相同也可以不同；或者是其药用活性盐，包括所有立体异构体形式，包括单对映异构体和对映体以及它们的混合物。已经发现这些化合物是高潜力的NK-3受体拮抗剂，用于治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑和注意力缺陷多动障碍（ADHD）。